Gilead Sciences Pre-Tax Profit Margin 2006-2021 | GILD

Current and historical pre-tax profit margin for Gilead Sciences (GILD) from 2006 to 2021. Pre-tax profit margin can be defined as earnings before taxes as a portion of total revenue. Gilead Sciences pre-tax profit margin for the three months ending September 30, 2021 was .
Gilead Sciences Pre-Tax Profit Margin Historical Data
Date TTM Revenue TTM Pre-Tax Income Pre-Tax Margin
2021-09-30 $27.48B $9.33B 33.96%
2021-06-30 $26.64B $6.72B 25.23%
2021-03-31 $25.56B $1.93B 7.55%
2020-12-31 $24.69B $1.67B 6.76%
2020-09-30 $23.15B $1.76B 7.59%
2020-06-30 $22.17B $-0.57B -2.57%
2020-03-31 $22.72B $4.81B 21.19%
2019-12-31 $22.45B $5.16B 22.99%
2019-09-30 $22.37B $4.28B 19.11%
2019-06-30 $22.36B $8.44B 37.75%
2019-03-31 $22.32B $8.12B 36.36%
2018-12-31 $22.13B $7.80B 35.25%
2018-09-30 $22.28B $8.91B 39.98%
2018-06-30 $23.20B $9.92B 42.75%
2018-03-31 $24.69B $11.95B 48.38%
2017-12-31 $26.11B $13.53B 51.82%
2017-09-30 $27.48B $15.32B 55.76%
2017-06-30 $28.47B $15.93B 55.95%
2017-03-31 $29.10B $16.21B 55.71%
2016-12-31 $30.39B $17.10B 56.26%
2016-09-30 $31.58B $18.61B 58.95%
2016-06-30 $32.37B $19.81B 61.20%
2016-03-31 $32.84B $20.92B 63.71%
2015-12-31 $32.64B $21.66B 66.36%
2015-09-30 $31.45B $20.45B 65.04%
2015-06-30 $29.19B $18.35B 62.86%
2015-03-31 $27.49B $17.15B 62.38%
2014-12-31 $24.89B $14.86B 59.69%
2014-09-30 $20.70B $11.74B 56.72%
2014-06-30 $17.44B $9.45B 54.18%
2014-03-31 $13.67B $6.22B 45.49%
2013-12-31 $11.20B $4.21B 37.57%
2013-09-30 $10.67B $4.12B 38.59%
2013-06-30 $10.31B $3.99B 38.68%
2013-03-31 $9.95B $3.88B 39.02%
2012-12-31 $9.70B $3.61B 37.23%
2012-09-30 $9.31B $3.41B 36.60%
2012-06-30 $9.01B $3.43B 38.11%
2012-03-31 $8.74B $3.45B 39.42%
2011-12-31 $8.39B $3.65B 43.55%
2011-09-30 $8.18B $3.63B 44.39%
2011-06-30 $8.00B $3.62B 45.24%
2011-03-31 $7.79B $3.63B 46.59%
2010-12-31 $7.95B $3.91B 49.23%
2010-09-30 $7.98B $4.17B 52.27%
2010-06-30 $7.85B $4.10B 52.29%
2010-03-31 $7.57B $3.87B 51.10%
2009-12-31 $7.01B $3.50B 49.96%
2009-09-30 $6.41B $3.16B 49.28%
2009-06-30 $5.98B $2.95B 49.31%
2009-03-31 $5.61B $2.79B 49.83%
2008-12-31 $5.34B $2.67B 50.10%
2008-09-30 $5.00B $2.44B 48.84%
2008-06-30 $4.69B $2.34B 49.85%
2008-03-31 $4.46B $2.31B 51.68%
2007-12-31 $4.23B $2.21B 52.27%
2007-09-30 $4.03B $0.20B 5.03%
2007-06-30 $3.72B $-0.28B -7.63%
2007-03-31 $3.36B $-0.46B -13.54%
2006-12-31 $3.03B $-0.64B -21.12%
2006-09-30 $2.74B $1.26B 46.20%
2006-06-30 $2.48B $1.44B 58.02%
2006-03-31 $2.29B $1.33B 57.99%
2005-12-31 $2.03B $1.16B 57.33%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $84.382B $24.689B
Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The Company strive to transform and simplify care for people with life-threatening illnesses around the world. Gilead's portfolio of products and pipeline of investigational drugs includes treatments for HIV/AIDS, liver diseases, cancer, inflammatory and respiratory diseases, and cardiovascular conditions. Their portfolio of marketed products includes a number of category firsts, including complete treatment regimens for HIV infection available in a once-daily single pill and the first oral antiretroviral pill available to reduce the risk of acquiring HIV infection in certain high-risk adults.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $141.747B 8.96
Bio-Rad Laboratories (BIO.B) United States $17.038B 34.58
QIAGEN (QGEN) Netherlands $10.791B 18.27
Biohaven Pharmaceutical Holding (BHVN) United States $7.896B 0.00
Emergent Biosolutions (EBS) United States $2.380B 8.56
Arcus Biosciences (RCUS) United States $2.057B 0.00
Myovant Sciences (MYOV) United Kingdom $1.157B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.011B 0.00
Zymeworks (ZYME) Canada $0.386B 0.00
Ambrx Biopharma (AMAM) United States $0.188B 0.00
SQZ Biotechnologies (SQZ) United States $0.178B 0.00
Enzo Biochem (ENZ) United States $0.154B 19.88